Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.
about
Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic CancerRadioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies.The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.Antigen specificity and tumour targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivativesOrthotopic xenografts of human melanoma and colonic and ovarian carcinoma in sheep to evaluate radioimmunotherapy.Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification.Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)Advances in radioimmunotherapy in the age of molecular engineering and pretargeting.A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma.Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in micePharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragmentsTwenty years with monoclonal antibodies: State of the art--Where do we go?Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy.Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.Preclinical Optimization of Antibody-based Radiopharmaceuticals for Cancer Imaging and Radionuclide Therapy - Model, Vector, and Radionuclide Selection.Production and tumour-binding characterization of a chimeric anti-CEA Fab expressed in Escherichia coli.
P2860
Q28552050-F63B2186-30FC-4FB2-907B-94DA1F4FC17AQ36079638-D9A6E950-F2A7-4E91-B589-71AEA8F1EC3FQ36080676-D0CE9D44-1E97-4BDF-8801-7922DF4FDA52Q36114727-8AD216CF-5E9D-4DB2-A674-92C2E80608EEQ36115373-27F5EDBD-5072-4CA4-A0ED-25C62AAD5E59Q36134492-7788653E-3888-4CA6-90FA-4A510AFF6065Q36135881-C21E36D0-F2B2-44DE-8F6D-E026D0BCC94DQ36391426-4B16B1AF-F0E5-4277-8CBD-97A32857C586Q36704446-A0DCA6DB-0D08-49EA-B378-B3FB3B035D6AQ36858256-E7B1A0A8-A899-4FF3-BF56-82FB83A59CF4Q38072598-229CF7EC-CF0D-4EAB-90BD-1E72948E1430Q40000687-4A7EA89E-CCEA-44DA-B315-5BA18263AFFBQ40788554-FDA6A8FA-BBFC-420B-BB75-DAB8EEE83312Q40960622-EECB352A-F1E4-4A9A-930F-9DCAA1D9297CQ41014959-2084BEBF-CF73-40B4-B84D-2A20E9291C23Q41810145-34F753B4-2F2B-4F61-9AAF-7E81791AD0C4Q48089417-5D363515-2899-48AF-9F80-413B8FC7C10EQ54636185-C2A3F411-3C93-48AA-908B-58959235356A
P2860
Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Comparative radioimmunotherapy ...... in a colonic xenograft model.
@ast
Comparative radioimmunotherapy ...... in a colonic xenograft model.
@en
type
label
Comparative radioimmunotherapy ...... in a colonic xenograft model.
@ast
Comparative radioimmunotherapy ...... in a colonic xenograft model.
@en
prefLabel
Comparative radioimmunotherapy ...... in a colonic xenograft model.
@ast
Comparative radioimmunotherapy ...... in a colonic xenograft model.
@en
P2093
P2860
P356
P1476
Comparative radioimmunotherapy ...... in a colonic xenograft model.
@en
P2093
P2860
P2888
P356
10.1038/BJC.1993.288
P407
P577
1993-07-01T00:00:00Z